Life sciences partner Greg Levine, counsel Beth Weinman and associate Joshua Oyster (all of Washington, D.C) authored a Law360 article published on May 10. The article examines two recent U.S. Food and Drug Administration draft guidances on inspections of medical device manufacturers, including the process for firms to request nonbinding, post-inspection FDA feedback on proposed corrective actions.
The authors note that the FDA draft guidances interpret certain statutory provisions in a way that is more restrictive and less impactful than the industry may have anticipated. As a result, the practical value of these reforms have may be limited unless the FDA revises the draft guidances.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.